BioTime, Inc. (BTX) Receives Average Recommendation of “Hold” from Analysts

Shares of BioTime, Inc. (NYSEMKT:BTX) have received a consensus recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $6.25.

A number of brokerages have weighed in on BTX. BidaskClub upgraded shares of BioTime from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Zacks Investment Research downgraded shares of BioTime from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. ValuEngine upgraded shares of BioTime from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $6.50 price objective (up previously from $6.00) on shares of BioTime in a research report on Monday, June 19th.

TRADEMARK VIOLATION WARNING: This news story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://sportsperspectives.com/2017/09/12/biotime-inc-btx-receives-average-recommendation-of-hold-from-analysts.html.

In related news, Director Broadwood Partners, L.P. purchased 10,000 shares of BioTime stock in a transaction that occurred on Tuesday, August 22nd. The stock was purchased at an average price of $2.60 per share, for a total transaction of $26,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders have purchased 175,896 shares of company stock valued at $487,120.

A number of hedge funds have recently added to or reduced their stakes in the business. Family Management Corp raised its holdings in BioTime by 1.4% in the 2nd quarter. Family Management Corp now owns 140,371 shares of the biotechnology company’s stock valued at $442,000 after acquiring an additional 2,000 shares during the last quarter. Moors & Cabot Inc. raised its holdings in BioTime by 25.2% in the 2nd quarter. Moors & Cabot Inc. now owns 49,630 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 10,000 shares during the last quarter. State Street Corp raised its holdings in BioTime by 10.3% in the 2nd quarter. State Street Corp now owns 1,345,379 shares of the biotechnology company’s stock valued at $4,238,000 after acquiring an additional 125,833 shares during the last quarter. Williams Jones & Associates LLC raised its holdings in BioTime by 14.6% in the 2nd quarter. Williams Jones & Associates LLC now owns 80,740 shares of the biotechnology company’s stock valued at $254,000 after acquiring an additional 10,290 shares during the last quarter. Finally, Voya Investment Management LLC raised its holdings in BioTime by 38.3% in the 2nd quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 8,996 shares during the last quarter.

Shares of BioTime (BTX) traded up 1.06% on Tuesday, hitting $2.87. The stock had a trading volume of 204,460 shares. The company has a 50-day moving average of $2.74 and a 200-day moving average of $3.08. The company has a market cap of $332.36 million, a P/E ratio of 4.82 and a beta of 1.37. BioTime has a 52-week low of $2.47 and a 52-week high of $4.01.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply